Pharmaceutical Sciences And Biomedical Analysis Journal

SCIENTIFIC LITERATURE

Review Article

Pharmacological and Analytical Profile of Celecoxib

Ahmed Ramadan[1], Ahmed Abd-Elaziz[2], Elsayed M Ismail[3], Asmaa Maher[2], Karim M Hegazy[2], Mahmoud M Sebaiy[2*]

[1]Department of Microbiology, Zagazig University, Egypt

[2]Department of Medicinal Chemistry, Zagazig University, Egypt

[3]Department of Pharmacology, Zagazig University, Egypt

ARTICLE INFO

Received Date: June 28, 2022
Accepted Date: July 22, 2022
Published Date: July 25, 2022

KEYWORDS

Literature review
Celecoxib
Anti-inflammatory
Degradation products
Biological samples

Citation for this article: Ahmed Ramadan, Ahmed Abd-Elaziz, Elsayed M Ismail, Asmaa Maher, Karim M Hegazy, Mahmoud M Sebaiy. Pharmacological and Analytical Profile of Celecoxib. Pharmaceutical Sciences And Biomedical Analysis Journal. 2022; 4(1):128

Corresponding author:
Mahmoud M Sebaiy, Department of Medicinal Chemistry, Zagazig University, Zagazig, 44519, Egypt, Tel: +01062780060; Fax: 0552303266; Email: mmsebaiy@zu.edu.eg; sebaiym@gmail.com

ABSTRACT

Celecoxib is a selective COX-II inhibitor drug that is used as an anti-inflammatory, analgesic, and antipyretic drug. In this literature review, we will shed the light on its pharmacological action beside most of up-to-date reported methods that have been developed for its determination in its pure form, combined form with other drugs, combined form with its metabolites, and in biological samples.

INTRODUCTION

Eicosanoids are one of the local hormones found in many tissues. They have many physiological and pathological actions. One of their most important precursors is arachidonic acid that is liberated from membrane phospholipids and then oxygenated by separate routes via COX and LOX enzyme, or through free-radical pathways, yielding prostanoids, leucotrienes, epoxygenase products and isoprostanes, respectively [1,2].COX enzymes are found as at least three isoenzymes, COX-1, COX-2, COX-3 and also other variant enzymes exist [3,4]. Most of NSAIDs are non-selective that inhibit COX-1 and COX-2 so they have many adverse effects such as GIT adverse effect [5,6]. Nonetheless, coxib class such as celecoxib (Figure 1) are selective inhibitors that were developed to provide a better GI safety and tolerability than other non-selective drugs like ibuprofen and naproxen [6,7] and its chemical name is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H - pyrazol-1-yl] benzenesulfonamide [8,9]. The risk of gastrointestinal events was significantly lower with celecoxib than with naproxen (P=0.01) or ibuprofen (P=0.002); the risk of renal events was significantly lower with celecoxib than with ibuprofen (P=0.004) but was not significantly lower with celecoxib than with naproxen (P=0.19) [6].

Due to the current importance of this drug in treatment of inflammation related to many diseases, this literature focuses on its pharmacology and different analytical methods that have been developed for determination of this drug in different pharmaceutical and biological samples.

PHARMACOLOGY

Celecoxib is an anti-inflammatory, analgesic, and antipyretic drug. The mechanism of action of celecoxib is the inhibition of prostaglandin synthesis mainly through inhibition of COX-2 as compared to the inhibition of COX-1 activity. Celecoxib has been considered as being 375 times more selective for COX-2 than for COX-1 [10]. It is most effective when the pain is related to inflammation [11]. Celecoxib is absorbed

with peak plasma concentration at ~ 3 h (Tmax) after an oral dose administration and its half-life is ~ 11 h [12], metabolized by CYP2C9 [13], and excretedin urine and feces [14]. It is widely used in treatment of osteoarthritis – rheumatoid arthritis [15,16], familiar adenomatous polyposis [17], ankylosing spondylitis [18], and juvenile rheumatoid arthritis [19]. Celecoxib has some cardiovascular side effects such as atherothrombotic effects, myocardial infarction, stroke: lower risk at low doses for short-term treatment [20,21]. It has also some drug interactions such as clopidogrel, lithium, fluconazole, warfarin, human immunodeficiency virus protease inhibitors [13].

COX-2 is upregulated in several adult epithelial cancers and neuroblastomata, and celecoxib was shown to induce apoptosis and to inhibit neuroblastoma growth. Apart from COX-2 inhibition, another function of celecoxib concerns the potential to inhibit cell proliferation and stimulate apoptotic cell death at much lower concentrations than any other coxibs [22].

REVIEW OF ANALYTICAL METHODS

Various techniques were used for the analysis of celecoxibin pure forms, in their pharmaceutical formulations and in biological fluids. The available reported methods in the literature can be summarized as follows:



Figure 1: Chemical Structure of Celecoxib.

Spectroscopic methods

Spectrophotometric methods

Drugs	Matrix	Method or reagent	λ_{max}(nm)	Linearity range	LOD	Ref.
Celecoxib	Capsule	UV spectrophotometry	270	20-40 µg/mL	-------	[23]
Celecoxib	Tablet	Ion association complex formation Charge transfer complexation reaction	665 511	0.2-1 µg/mL	0.37 µg/mL 0.426 µg/mL	[24]
Celecoxib	Capsule	UV spectrophotometry	251	1–20 µg/mL	0.26 µg/mL	[25]
Celecoxib and amlodipine besylate	Tablet	Dual-wavelength method Simultaneous equation method	252–357 252	1-25 µg/mL	0.33 µg/mL 0.25 µg/mL	[26]
Celecoxib and amlodipine besylate	Tablet	Vierordt's simultaneous equation method Q-analysis method	255 250	10-50µg/mL	0.343 µg/mL	[27]
Celecoxib and amlodipine	Capsule	First Derivative Spectrophotometric Method Ratio First Derivative Spectroscopy	289.4 286.7	5-40 µg/mL	0.45 µg/mL 0.34 µg/mL	[28]
Celecoxib and amlodipine	Capsule	Absorption correction method Induced dual-wavelength method Fourier self deconvoluted method	253 251-270 269	10-30 µg/mL 5-30 µg/mL 5-30 µg/mL	1.0450 µg/mL 0.6497 µg/mL 0.6737 µg/mL	[29]

Spectrofluorometric methods

Drugs	Matrix	Fluorogenic reagent (method)	λ_{ex} (nm)	λ_{em} (nm)	Linearity range	LOD	Ref.
Celecoxiband flurbiprofen	Capsule	Water	256	403	50-1000 ng/mL	4.97 ng/mL	[30]
Celecoxib	Capsule	Ethanol acetonitrile	272±3	355±5	0.13–2.00 mg/L 0.19–2.32 mg/L	0.04 mg/L 0.06 mg/L	[31]

Chromatographic methods

HPLC methods

Drugs	Matrix	Column	Mobile Phase	Detector	Linearity range	LOD	Ref.
Celecoxib	Human plasma	Luna HILIC column (50 mm × 2.0 mm, 3 µm, Phenomenex, USA)	Formate buffer (pH3.0):methanol (5:95, v/v)	MS/MS	10-2000 ng/mL	3.03 ng/mL	[32]
Celecoxib, hydroxycelecoxib and celecoxib carboxylic acid	Rat plasma	Atlantis T3 column (2.1 mm × 100 mm, 3 µm, Waters, USA)	Ammonium formate : 5% or 95% acetonitrile	MS/MS	5-4000 ng/mL	1.51 ng/mL	[33]
Celecoxib, Erlotinib, and Desmethyl-Erlotinib	Rat Plasma	C_{18} column (50mm × 4.6mm, 3µ, YMC®-PACK, JAPAN)	Methanol: ammonium acetate buffer (80:20, v/v)	MS/MS	1.8-1289.2 ng/mL	0.45 ng/mL	[34]
Celecoxib	Human plasma	Shim Pack GLC-CN, C_{18} column (150 mm×6 mm, 5 µm)	Acetonitrile:1% acetic acid (4:1)	MS	50-1000 ng/mL	20 ng/mL	[35]
Celecoxib	Human and rat plasma	NucleosilRP C_{18} column (30 x 2 mm, 5 µm)	Acetonitrile:water :ammonium hydroxide solution (65:35:0.1, v/v/v)	MS/MS	0.25-250 ng/mL	0.075 ng/mL	[36]
Celecoxib, amlodipine and 4-methylacetophenone	Tablet	ZORBAX Eclipse Plus C_{18} column (4.6 mm × 100 mm, 3.5 µm)	Methanol:formic acid (95:5 v/v)	MS/MS	0.001–50 µg/mL	0.00027 µg/mL	[37]
Celecoxib	Human plasma	ACE C_8-300 column (50 × 4.0 mm, 3.0 µm)	Methanol: ammonium acetate 80:20 (v/v)	MS/MS	10.0-4000 ng/mL	2.50 ng/mL	[38]
Celecoxib and amlodipine	Tablet	Thermo ODS Hypersil C_{18} column (4.6 × 250 mm, 5 µm)	Acetonitrile: potassium phosphate buffer (pH 5.5) 60:40 (v/v)	Fluorescence detector(λ_{ex}265 and λ_{em}359 nm)	0.05-10 µg/mL	0.0167 µg/mL	[39]
Celecoxib and docetaxel	Rat plasma	C_{18} µ-Bondapack column (250 mm × 4.6 mm, Waters)	Acetonitrile:water (45:55, v/v)	UV detector at230 nm	0.05-4 µg/mL	0.015µg/mL	[40]
Celecoxib	Porcine skin	LiChrospher RP-C_{18} column (10 cm, 5 µm, 4 mm)	Methanol:water(72:28, v/v)	UV detector at 251 nm	0.1-3.0 µg/mL in the AS layer 5.0-50.0 µg/mL inSC layer and [EP + D]	0.1 µg/mL	[41]
Celecoxib and	Capsule	Inertsil ODS 3V	Gradient mobile phase Solution A (pH	UV detector at	10-40	0.021 to	[42]

diacerein		column (250 × 4.6 mm; 5 µm, GL Sciences, Inc., Japan)	= 2.3 buffer) and Solution B (methanol and acetonitrile; 50 : 50, v/v)	255 nm	µg/mL	0.027 µg/mL	
Celecoxib and repaglinide	Rat plasma	Kinetex C_{18} column (250 × 4.6 mm, 5 µm, 100 Å)	Acetonitrile: phosphate buffer pH 6.0.	Fluorescence detector (λ_{ex}240 and λ_{em} 380 nm)	10-2000 ng/mL	3.03 ng/mL	[43]
Celecoxib	Human plasma	Nova Pak C_8 column (3.8 × 150 mm,	Acetonitrile: tetrahydrofuran: 0.02M sodium acetate buffer (30:8:62)	UV detector at 252 nm	40–4000 ng/mL	12.12 ng/mL	[44]
Celecoxib	Human plasma	Nucleosil-NO_2 column (150 x 4.6 mm, 5 µm)	Hexane:methylenechloride:isopropyl alcohol (70:25:5, v/v).	UV detector at 260 nm	25-2000 ng/mL	7.57 ng/mL	[45]
Celecoxib	Human Serum	Prontosil C_{18} AQ column (150×3 mm, 3µm)	Water:acetonitrile (40:60, v/v)	Fluorescence detector (λ_{ex}240 and λ_{em} 380 nm)	12.5-1500 ng/mL	3.78 ng/mL	[46]
Celecoxib and rofecoxib	Human plasma	Zorbax SB-CN (5 µm) column	Acetonitrile: potassium dihydrogen orthophosphate buffer pH 2.4 (42:58, v/v)	UV detector at 254 nm	20-2000 µg/L	6.06 µg/L	[47]
Celecoxiband doxorubicin	Nanoparticulate fixed dose combination (NanoFDC)	Inertsil ODS-3 C_{18} column (250 mm x 4.6 mm, 5 µm)	Acetic acid (pH 3.0, 1 %): acetonitrile(40:60 v/v)	Fluorescence detector (λ_{ex}480 and λ_{em} 590 nm)	1-11 µg/mL	13 ng/mL	[48]
Celecoxib	Human plasma	Knauer C_{18} column (4.6 mm. x 250 mm, 5 µm)	Acetonitrile:water (75/25, v/v)	UV detector at 250 nm	0.2–2000 µg/L	0.08µg/L	[49]
Celecoxib	Human plasma and breast milk	Aqua C_{18} (75 mm × 4.6 mm 5 µm)	Acetonitrile: phosphate buffer pH 3.5 (50:50, v/v) containing 0.1% triethylamine	UV detector at 254 nm	10-2000 µg/L	3.03 µg/L	[50]
Celecoxib, etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide	Human plasma	Kromasil KR 100-5 C_{18} column (4.6 x 250 mm, 5 µm)	Gradient mobile phase Formic acid (pH 3): acetonitrile:methanol:water	UV detector at 235 nm	0.1-50 µg/mL	0.03 µg/mL	[51]
Celecoxib	Human plasma	Monolithic silica column (RP-18e, 100 mm × 4.6 mm)	Acetonitrile:methanol: distilled water (45:10:45, v/v/v) containing 0.2% acetic acid (pH 3.5)	UV detector at 254 nm	10-800 ng/mL	3.03 ng/mL	[52]
Celecoxib	Human plasma	Nucleosil C_8 column (120-5, 11 x 2 mm)	----------	UV detector at 253 nm	5-2000 µg/L	1.5 µg/L	[53]
Celecoxib, hydroxycelecoxib, and carboxycelecoxib	Human plasma	Phenomenex Luna C_{18} column (5 µm, 150×4.6 mm)	Gradient mobile phase acetonitrile:sodium hydrogen phosphate buffer (pH5.4)	UV detector at 254 nm	10-500 ng/mL	3.03 ng/mL	[54]
Celecoxib, alprazolam and diclofenac sodium	Tablet and human serum	Shimadzu Shim-pack CLC-ODS 25M column (4.6 mm × 0.25mm)	Methanol: water (pH 3.5) (80:20,v/v)	UV detector at 230 nm	0.3-20 µg/mL	17.29 ng/mL	[55]
Celecoxib	Human plasma	Nucleosil 100-5 CN column (5 µm, 250×4.6 mm)	Acetonitrile:water (60:40 (v/v))	UV detector at 260 nm	10-1000 ng/mL	3.03 ng/mL	[56]
Celecoxib, rofecoxib, valdecoxib, nimesulide and nabumetone	Tablet and human serum	Inertsil C_{18} column (5 µm, 250×4.6 mm)	Methanol:glacial acetic acid (68:32, v/v)	UV detector at 230 nm	1-20 µg/mL	1.040 µg/mL	[57]

HPTLC methods

Drugs	Matrix	Stationary phase	Mobile phase	Detector	Linearity range	LOD	Ref.
Celecoxib, amlodipine and 4-methylacetophenone	Tablet	Silica gel 60F_{254} plates	Methanol: water: ammonia (70:25:1.5, v/v/v)	UV at 264 nm	1–150 µg/band	0.291 µg/band	[37]
Celecoxib	Capsule	Silica gel 60F_{254} plates	n-hexane–ethyl acetate, 60 + 40 (v/v)	UV at 262 nm	200 - 2000 ng	------	[58]
12 NSAIDS drugs	Urine	Silica gel 60F_{254} plates	Ethyl acetate–toluene–methanol–acetic acid 40:40:1:1 (v/v)	UV at 254 nm	0.5–5 µg/spot	0.005-0.5 µg/spot	[59]
Celecoxib, piroxicam, tenoxicam, and rofecoxib	Human whole blood and urine	Silica gel F_{254} plates	Ethyl acetate–toluene–butylamine (2 : 2 : 1, v/v/v) and chloroform–acetone–toluene (6 : 2.5 : 1, v/v/v)	UV at 254 nm	2.8 - 38.6 µg/mL	0.06 µg/mL	[60]

Electrochemical methods

Drugs	Matrix	Electrode	Linearity range	LOD	Ref.
Celecoxib	Capsule and human serum	Mercury electrode surface in Britton–Robinson buffer of pH 7.0	1×10^{-9}–2×10^{-8} M	1.86×10^{-10} M	[61]
Celecoxib	Tablets	Graphene Based Carbon Ionic Liquid Electrode Modified with Gold Nanoparticles	0.5-15 µM	0.2 µM	[62]
Celecoxib	Tablet and human serum	Pencil graphite electrode (PGE) modified with functionalized multi-walled carbon nanotubes (MWCNTs).	5.0×10^{-3}–20 µM	2.34×10^{-3} µM	[63]
Celecoxib	----------	Polyaniline grafted multiwall carbon nanotubes modified electrode	1×10^{-11}–1×10^{-6} M	----------	[64]

CONCLUSION

This literature review represents an up to date survey about pharmacological action and all reported methods that have been developed for determination of celecoxibits pure form, combined form with other drugs, combined form with its metabolites, and in biological samples such as liquid chromatography, spectrophotometry, spectroflourimetry, electrochemistry, etc...

REFERENCES

1. Rajakariar R, Yaqoob MM, Gilroy DW. (2006). COX-2 in inflammation and resolution. Molecular interventions. 6: 199-207.
2. FitzGerald GA. (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Reviews Drug Discovery. 2: 879-890.
3. Tanaka Y, Ward SL, Smith WL. (1987). Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes. Journal of Biological Chemistry. 262: 1374-1381.
4. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. (1991). Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proceedings of the National Academy of Sciences. 88: 2692-2696.
5. Gabriel SE, Jaakkimainen L, Bombardier C. (1991). Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Annals of internal medicine. 115: 787-796.
6. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, et al. (2016). Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England Journal of Medicine. 375: 2519-2529.
7. Griswold DE, Adams JL. (1996). Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Medicinal research reviews. 16: 181-206.
8. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, et al. (1997). Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). Journal of medicinal chemistry. 40: 1347-1365.
9. Primo FT, Fröhlich PE. (2005). Celecoxib identification methods. Acta Farmaceutica Bonaerense. 24: 421-425.
10. Furst DE, Munster T. (2001). Nonsteroid anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics and drug used in gout. In: Basic and Clinical

Pharmacology. Katsung BG (Ed.), Lange Medical Books/McGraw-Hill Companies, USA : 596 -624.

https://accessmedicine.mhmedical.com/content.aspx?bookid=2249&sectionid=175221264

11. Camu F, Shi L, Vanlersberghe C. (2003). The role of COX-2 inhibitors in pain modulation. Drugs. 63: 1-7.
12. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, et al. (2001). Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. Journal of Pharmacology and Experimental Therapeutics. 297: 638-645.
13. Rodrigues AD. (2005). Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug metabolism and disposition. 33: 1567-1575.
14. Sandberg M, Yasar Ü, Strömberg P, Höög JO, Eliasson E. (2002). Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. British journal of clinical pharmacology. 54: 423-429.
15. Deeks JJ, Smith LA, Bradley MD. (2002). Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Bmj. 325: 619.
16. Fidahic M, Kadic AJ, Radic R, Puljak L. (2017). Celecoxib for rheumatoid arthritis. Cochrane Database Syst. Rev. 6: CD012095.
17. Asano TK, McLeod RS. (2004). Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database of Systematic Reviews. CD004079.
18. Ilowite NT. (2002). Current treatment of juvenile rheumatoid arthritis. Pediatrics. 109: 109-115.
19. Moore RA, Derry S, Makinson GT, McQuay HJ. (2005). Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis research & therapy. 7: 644-665.
20. Brophy JM. (2005). Celecoxib and cardiovascular risks. Expert opinion on drug safety. 4: 1005-1015.
21. Krötz F, Schiele TM, Klauss V, Sohn HY. (2005). Selective COX-2 inhibitors and risk of myocardial infarction. Journal of vascular research. 42: 312-324.
22. Johnsen JI, Lindskog M, Ponthan F, pettersen I, Elfman L, et al. .(2005): NSAIDs in neuroblastoma therapy. Cancer Lett. 228 : 195 -201.
23. Karajgi SR, Metri S, Tiwari V, Hulyalkar S, Rub TA, et al. (2016). UV spectrophotometric method for the quantitative estimation of celecoxib in capsule dosage forms. Der Pharmacia Lettre. 8: 247-257.
24. Ghashim LL. (2013). Spectrophotometric Determination of Celecoxib in Pharmaceutical Preparations. Journal of the college of basic education. 19: 673-682.
25. Saha RN, Sajeev C, Jadhav PR, Patil SP, Srinivasan N. (2002). Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography. Journal of pharmaceutical and biomedical analysis. 28: 741-751.
26. Mabrouk M, Abdel Hamid M, Michael M. (2021). Green Simultaneous Determination of Amlodipine Besylate and Celecoxib by Dual wavelength and Simultaneous Equation Spectrophotometric Methods. Journal of Advanced Medical and Pharmaceutical Research. 2: 16-23.
27. Kushwaha D, Diwakar S, Roy RK, Karole S, Kushwaha H, et al. (2019). Novel UV spectrophotometer methods for quantitative estimation of concensi (amlodipine 10mg and celecoxib 200mg) using hydrotropic solubilizing agents. Journal of Drug Delivery and Therapeutics. 9: 651-655.
28. Attimarad M, Venugopala KN, Aldhubiab BE, Nair AB, Sree Harsha N, et al. (2019). Development of UV spectrophotometric procedures for determination of amlodipine and celecoxib in formulation: use of scaling factor to improve the sensitivity. Journal of Spectroscopy.
29. Attala K, Elsonbaty A. (2021). Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 244: 118853.
30. Jadhav PR, Kharwade PB, Saha RN. (2006). Rapid and sensitive spectrofluorimetric method for the estimation of celecoxib and flurbiprofen. Indian journal of pharmaceutical sciences. 68: 20.
31. Damiani P, Bearzotti M, Cabezón MA. (2003). A validated spectrofluorometric method for the determination of celecoxib in capsules. Analytical and bioanalytical chemistry. 376: 1141-1146.
32. Park MS, Shim WS, Yim SV, Lee KT. (2012). Development of simple and rapid LC–MS/MS method for determination of celecoxib in human plasma and its application to

bioequivalence study. Journal of Chromatography B. 902: 137-141.

33. Oh HA, Kim D, Lee SH, Jung BH. (2015). Simultaneous quantitative determination of celecoxib and its two metabolites using liquid chromatography–tandem mass spectrometry in alternating polarity switching mode. Journal of pharmaceutical and biomedical analysis. 107: 32-39.
34. Thappali SR, Varanasi K, Veeraraghavan S, Arla R, Chennupati S, et al. (2012). Simultaneous determination of celecoxib, erlotinib, and its metabolite desmethyl-erlotinib (OSI-420) in rat plasma by liquid chromatography/tandem mass spectrometry with positive/negative ion-switching electrospray ionisation. Scientia pharmaceutica. 80: 633-646.
35. Abdel-Hamid M, Novotny L, Hamza H. (2001). Liquid chromatographic–mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. Journal of Chromatography B: Biomedical Sciences and Applications. 753: 401-408.
36. Bräutigam L, Vetter G, Tegeder I, Heinkele G, Geisslinger G. (2001). Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications. 761: 203-212.
37. Z Sharkawi MM, Mohamed NR, El-Saadi MT, Amin NH. (2021). Validated green chromatographic methods for determination of amlodipine and celecoxib in presence of methylacetophenone. Bioanalysis. 13: -969-983.
38. Patel NP, Mallika S, Shrivastav PS, Patel BN. (2018). Estimation of celecoxib in human plasma by rapid and selective LC-MS/MS method for a bioequivalence study. Int J Pharm Pharm Sci. 10: 16-22.
39. Abdel Hamid MA, Mabrouk MM, Michael MA. (2020). A fast and green reversed-phase HPLC method with fluorescence detection for simultaneous determination of amlodipine and celecoxib in their newly approved fixed-dose combination tablets. Journal of Separation Science. 43: 3197-3205.
40. Ziaei E, Emami J, Kazemi M, Rezazadeh M. (2020). Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: *in vitro* and *in vivo* Validation and Application. 23: 289-303.
41. Praça FSG, Bentley MVLB, Lara MG, Pierre MBR. (2011). Celecoxib determination in different layers of skin by a newly developed and validated HPLC-UV method. Biomedical Chromatography, 25(11), 1237-1244.
42. Bapatu HR, Maram RK, Murthy RS. (2015). Stability-indicating HPLC method for quantification of celecoxib and diacerein along with its impurities in capsule dosage form. Journal of chromatographic science. 53: 144-153.
43. Han DG, Kwak J, Seo SW, Kim JM, Yoo JW, et al. (2019). Pharmacokinetic evaluation of metabolic drug interactions between repaglinide and celecoxib by a bioanalytical HPLC method for their simultaneous determination with fluorescence detection. Pharmaceutics. 11: 382.
44. Chow HHS, Anavy N, Salazar D, Frank DH, Alberts DS. (2004). Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography. Journal of pharmaceutical and biomedical analysis. 34: 167-174.
45. Rose MJ, Woolf EJ, Matuszewski BK. (2000). Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection. Journal of Chromatography B: Biomedical Sciences and Applications. 738: 377-385.
46. Schönberger F, Heinkele G, Mürdter TE, Brenner S, Klotz U, et al. (2002). Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B. 768: 255-260.
47. Hamama AK, Ray J, Day RO, Brien JAE. (2005). Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography. Journal of chromatographic science. 43: 351-354.
48. Kozlu S, Sahin A, Calis S, Yilmaz C. (2017). Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC). Die Pharmazie. 72: 568-570.
49. Arabi M, Ghaedi M, Ostovan A. (2017). Development of a lower toxic approach based on green synthesis of water-compatible molecularly imprinted nanoparticles for the extraction of hydrochlorothiazide from human urine. ACS Sustainable Chemistry & Engineering. 5: 3775-3785.
50. Zhang M, Moore GA, Gardiner SJ, Begg EJ. (2006). Determination of celecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. Journal of Chromatography B. 830: 245-248.

51. Pavan Kumar VV, Vinu MC, Ramani AV, Mullangi R, Srinivas NR. (2006). Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomedical Chromatography. 20: 125-132.
52. Zarghi A, Shafaati A, Foroutan SM, Khoddam A. (2006). Simple and rapid high-performance liquid chromatographic method for determination of celecoxib in plasma using UV detection: application in pharmacokinetic studies. Journal of Chromatography B. 835: 100-104.
53. Werner U, Werner D, Pahl A, Mundkowski R, Gillich, M, et al. (2002). Investigation of the pharmacokinetics of celecoxib by liquid chromatography–mass spectrometry. Biomedical Chromatography. 16: 56-60.
54. Stormer E, Bauer S, Kirchheiner J, Brockmoller J, Roots I. (2003). Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 783: 207-212.
55. Ali SN, Akram S, Qayoom A, Naz N, Ayub A. (2020). Liquid chromatographic method for simultaneous determination of alprazolam with NSAIDs in bulk drug, pharmaceutical formulation and human serum. Pakistan journal of pharmaceutical sciences. 33: 121-127.
56. Jalalizadeh H, Amini M, Ziaee V, Safa A, Farsam H, et al. (2004). Determination of celecoxib in human plasma by high-performance liquid chromatography. Journal of pharmaceutical and biomedical analysis. 35: 665-670.
57. Rao RN, Meena S, Nagaraju D, Rao AR. (2005). Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. Biomed Chromatogr. 19: 362-368.
58. Sane R, Pandit S, Khedkar S. (2004). High-performance thin-layer chromatographic determination of celecoxib in its dosage form. JPC-Journal of Planar Chromatography-Modern TLC. 17: 61-64.
59. Tița B, Măruțoiu OF, Tița D, Măruțoiu C, Soran ML, et al. (2012). Separation and identification of some non-steroidal anti-inflammatory drugs using TLC and HPLC-MS. JPC–Journal of Planar Chromatography–Modern TLC. 25: 523-527.
60. Starek M, Krzek J, Rotkegel P. (2015). TLC determination of piroxicam, tenoxicam, celecoxib and rofecoxib in biological material. Journal of Analytical Chemistry. 70: 351-359.
61. Ghoneim MM, Beltagi AM. (2003). Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. Talanta. 60: 911-921.
62. Arkan E, Karimi Z, Shamsipur M, Saber R. (2013). Electrochemical determination of celecoxib on a graphene based carbon ionic liquid electrode modified with gold nanoparticles and its application to pharmaceutical analysis. Analytical Sciences. 29: 855-860.
63. Nezhadali A, Sadeghzadeh S. (2017). Experimental design-artificial neural network-genetic algorithm optimization and computer-assisted design of celecoxib molecularly imprinted polymer/carbon nanotube sensor. Journal of Electroanalytical Chemistry. 795: 32-40.
64. Manesh KM, Santhosh P, Komathi S, Kim NH, Park JW, et l. (2008). Electrochemical detection of celecoxib at a polyaniline grafted multiwall carbon nanotubes modified electrode. Analytica chimica acta. 626: 1-9.